AZD4954 / AstraZeneca - LARVOL DELTA

A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and the Absolute Bioavailability of AZD4954 (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: AstraZeneca

New P1 trial

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia (clinicaltrials.gov) - P1 | N=136 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Dec 2026 ➔ Apr 2027 | Trial primary completion date: Dec 2026 ➔ Apr 2027

Trial completion date • Trial primary completion date • Dyslipidemia • Metabolic Disorders

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults (clinicaltrials.gov) - P1 | N=31 | Completed | Sponsor: AstraZeneca | Recruiting ➔ Completed

Trial completion

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: AstraZeneca

New P1 trial